ArticleInternational seminars in surgical oncology : ISSO2007
Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease.
Article in International seminars in surgical oncology : ISSO, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 citations in OpenAlex.
- The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.BMC medical imaging · 2014Trial
- Article
- Comparison ofMolecular imaging · 2021Article
- Does Routine Triple-Time-Point FDG PET/CT Imaging Improve the Detection of Liver Metastases?Diagnostics (Basel, Switzerland) · 2020Article
- Imaging findings of hepatic epithelioid hemangioendothelioma and fibrolamellar hepatocellular carcinoma: a critical appraisal of current literature about imaging features of two rare liver cancers.Translational cancer research · 2019Review
- In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis byEJNMMI research · 2018Article
- [Research and application ofSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2017Review
- PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.In vivo (Athens, Greece) · 2017Article
- Implications of Ambient Glucose Variation on the Target-to-Background Ratio of Hepatic Tumors By (18)FDG-PET Imaging.Journal of clinical imaging science · 2014Article
- Use of benzodiazepines before (18)F-FDG-PET/CT dual-phase imaging does not decrease the efficacy of the study.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India · 2012Article
- Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?Korean journal of hepato-biliary-pancreatic surgery · 2011Article
- Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.Molecular imaging and biology · 2011Article
- The current role of PET-CT in the characterization of hepatobiliary malignancies.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2009Article
- Article
- Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.Journal of medicine and lifeReview
- Detection of Primary Hepatocellular Carcinoma onEuroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate determination of the extrahepatic extent and intrahepatic distribution of disease is very important in patients with primary and metastatic liver disease for deciding whether a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate the efficacy of delayed phase FDG-PET/CT imaging in lesion detection and to define its clinical impact compared to triple-phase contrast enhanced CT (CECT).
methods30 patients underwent delayed phase FDG-PET/CT imaging (90 min whole body scan followed by a delayed abdominal scan at 120 min). Maximum standard uptake values (SUVs) and SUV ratios between tumor and normal liver parenchyma (T/N) were evaluated. In addition, comparison was made to CECT obtained within 10 days of the FDG-PET/CT to evaluate for lesion concordance within individual liver segments (Couinaud designation).
resultsSites of primary malignancies included: colorectal (19), breast (3), pancreas (2), lung (2), carcinoid (2), cholangiocarcinoma (1), and hepatocellular carcinoma (1). There was a significant increase in SUV value of liver lesions between early and delayed acquisition (P < 0.001). Although there was not a significant reduction in liver background activity between the two studies, there was a strong increase in T/N ratio (P < 0.001) allowing better lesion detection by visual inspection. New lesions were identified in 5 of the 30 patients, which were not appreciated on the early scan. Delayed phase FDG-PET/CT identified one lesion which was not present on the corresponding CECT. Delayed phase FDG-PET/CT revealed extrahepatic sites of metastases not appreciated on CECT in 6 patients.
conclusionDelayed phase FDG-PET/CT protocol improved lesion detectability in primary and metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT identified extrahepatic disease not seen on CECT in 20% of the patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.